Terms: = Prostate cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE
118 results:
1. [LncRNA RPL22P1-201 affects prostate cancer cell proliferation, cell cycle, and sensitivity to docetaxel by regulating miR-216b-5p expression].
Yang C; Xue JG
Zhonghua Nan Ke Xue; 2023 Oct; 29(10):881-887. PubMed ID: 38639656
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of Proliferation and Induction of Apoptosis in Prostatic Carcinoma DU145 Cells by Polysaccharides from Yunnan
Yang Z; Chen G
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611854
[TBL] [Abstract] [Full Text] [Related]
3. Genetic susceptibility to prostate cancer in Taiwan: A genome-wide association study.
Bau DT; Tsai CW; Chang WS; Yang JS; Liu TY; Lu HF; Wang YW; Tsai FJ
Mol Carcinog; 2024 Apr; 63(4):617-628. PubMed ID: 38390760
[TBL] [Abstract] [Full Text] [Related]
4. Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
Sáez-Martínez P; Porcel-Pastrana F; Montero-Hidalgo AJ; Lozano de la Haba S; Sanchez-Sanchez R; González-Serrano T; Gómez-Gómez E; Martínez-Fuentes AJ; Jiménez-Vacas JM; Gahete MD; Luque RM
Cancer Lett; 2024 Mar; 584():216604. PubMed ID: 38244911
[TBL] [Abstract] [Full Text] [Related]
5. A review on the role of PCGEM1 lncRNA in cancer.
Ghafouri-Fard S; Khoshbakht T; Hussen BM; Baniahmad A; Taheri M; Mokhtari M
Pathol Res Pract; 2022 Dec; 240():154223. PubMed ID: 36403313
[TBL] [Abstract] [Full Text] [Related]
6. Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk prostate cancer (The Prospective SENTINELLE Study).
Lannes F; Baboudjian M; Ruffion A; Rouy M; Giammarile F; Rousseau T; Kraeber-Bodéré F; Rousseau C; Rusu D; Colombié M; Brenot-Rossi I; Rossi D; Mottet N; Bastide C
J Urol; 2023 Feb; 209(2):364-373. PubMed ID: 36331157
[TBL] [Abstract] [Full Text] [Related]
7. ZFP36 Inhibits Tumor Progression of Human prostate cancer by Targeting cdk6 and Oxidative Stress.
Yuan D; Fang Y; Chen W; Jiang K; Zhu G; Wang W; Zhang W; You G; Jia Z; Zhu J
Oxid Med Cell Longev; 2022; 2022():3611540. PubMed ID: 36111167
[TBL] [Abstract] [Full Text] [Related]
8. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant prostate cancer: An Indirect Comparison.
Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
[TBL] [Abstract] [Full Text] [Related]
9. cdk6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract] [Full Text] [Related]
10. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
11.
Moradi F; Duan H; Song H; Davidzon GA; Chung BI; Thong AEC; Loening AM; Ghanouni P; Sonn G; Iagaru A
J Nucl Med; 2022 Dec; 63(12):1822-1828. PubMed ID: 35512996
[TBL] [Abstract] [Full Text] [Related]
12. Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer.
Kushwaha PP; Verma SS; Shankar E; Lin S; Gupta S
Mol Carcinog; 2022 Apr; 61(4):397-407. PubMed ID: 34939235
[TBL] [Abstract] [Full Text] [Related]
13. AS1 expression in prostate cancer and its effects on proliferation and invasion of prostate cancer cells.
Li Y; Zhuang X; Zhuang L; Liu H
Cancer Biomark; 2021; 32(3):271-279. PubMed ID: 34151833
[TBL] [Abstract] [Full Text] [Related]
14. Genetic variants of CHEK1, PRIM2 and cdk6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.
Mu R; Liu H; Luo S; Patz EF; Glass C; Su L; Du M; Christiani DC; Jin L; Wei Q
Int J Cancer; 2021 Sep; 149(6):1302-1312. PubMed ID: 34058013
[TBL] [Abstract] [Full Text] [Related]
15. Landscape of Cyclin Pathway Genomic Alterations Across 5,356 prostate cancers: Implications for Targeted Therapeutics.
Jardim DL; Millis SZ; Ross JS; Woo MS; Ali SM; Kurzrock R
Oncologist; 2021 Apr; 26(4):e715-e718. PubMed ID: 33522043
[TBL] [Abstract] [Full Text] [Related]
16. Differential Regulation of cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
[TBL] [Abstract] [Full Text] [Related]
17. Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.
Jardim DL; Millis SZ; Ross JS; Woo MS; Ali SM; Kurzrock R
Oncologist; 2021 Jan; 26(1):e78-e89. PubMed ID: 32885893
[TBL] [Abstract] [Full Text] [Related]
18. Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants.
Larsson SC; Carter P; Kar S; Vithayathil M; Mason AM; Michaëlsson K; Burgess S
PLoS Med; 2020 Jul; 17(7):e1003178. PubMed ID: 32701947
[TBL] [Abstract] [Full Text] [Related]
19. Baicalin suppresses the cell cycle progression and proliferation of prostate cancer cells through the cdk6/FOXM1 axis.
Yu Z; Zhan C; Du H; Zhang L; Liang C; Zhang L
Mol Cell Biochem; 2020 Jun; 469(1-2):169-178. PubMed ID: 32385718
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced prostate cancer.
Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
[TBL] [Abstract] [Full Text] [Related]
[Next]
